140 Applying Pharmacogenomics in TherapeuticsTai, Y.C., Domchek, S., Parmigiani, G., and Chen, S. (2007). Breast cancer risk among maleBRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute 99,1811–1814.Takeuchi, K., Choi, Y.L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., et al. (2009).KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-baseddiagnostic system for ALK-positive lung cancer. Clinical Cancer Research 15, 3143–3149.Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., et al.(2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.The New England Journal of Medicine 354, 2531–2541.Thompson, D., Easton, D.F., and Breast Cancer Linkage Consortium. (2002). Cancer incidencein BRCA1 mutation carriers. Journal of the National Cancer Institute 94, 1358–1365.Tulinius, H., Olafsdottir, G.H., Sigvaldason, H., Arason, A., Barkardottir, R.B., Egilsson, V.,Ogmundsdottir, H.M., Tryggvadottir, L., Gudlaugsdottir, S., and Eyfjord, J.E. (2002).The effect of a single BRCA2 mutation on cancer in Iceland. Journal of MedicalGenetics 39, 457–462.van der Groep, P., van der Wall, E., and van Diest, P.J. (2011). Pathology of hereditary breastcancer. Cellular Oncology 34, 71–88.Walker, A.H., Jaffe, J.M., Gunasegaram, S., Cummings, S.A., Huang, C.S., Chern, H.D.,Olopade, O.I., Weber, B.L., and Rebbeck, T.R. (1998). Characterization of an allelic variantin the nifedipine-specific element of CYP3A4: Ethnic distribution and implications forprostate cancer risk. Mutations in brief no. 191. Online. Human Mutation 12, 289.Walsh, T., and King, M.C. (2007). Ten genes for inherited breast cancer. Cancer Cell 11,103–105.Walsh, T., Lee, M.K., Casadei, S., Thornton, A.M., Stray, S.M., Pennil, C., Nord, A.S.,Mandell, J.B., Swisher, E.M., and King, M.C. (2010). Detection of inherited mutationsfor breast and ovarian cancer using genomic capture and massively parallelsequencing. Proceedings of the National Academy of Sciences of the United States ofAmerica 107, 12629–12633.Wang, J., Mougey, E.B., David, C.J., Humma, L.M., Johnson, J.A., Lima, J.J., andSylvester, J.E. (2001). Determination of human beta(2)-adrenoceptor haplotypes bydenaturation selective amplification and subtractive genotyping. American Journal ofPharmacogenomics 1, 315–322.Weinshilboum, R.M., and Sladek, S.L. (1980). Mercaptopurine pharmacogenetics: Monogenicinheritance of erythrocyte thiopurine methyltransferase activity. American Journal ofHuman Genetics 32, 651–662.Wilke, R.A., Ramsey, L.B., Johnson, S.G., Maxwell, W.D., McLeod, H.L., Voora, D.,Krauss, R.M., et al. (2012). The clinical pharmacogenomics implementation consortium:CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. ClinicalPharmacology and Therapeutics 92, 112–117.Win, A.K., Young, J.P., Lindor, N.M., Tucker, K.M., Ahnen, D.J., Young, G.P., Buchanan, D.D.,et al. (2012). Colorectal and other cancer risks for carriers and noncarriers from familieswith a DNA mismatch repair gene mutation: A prospective cohort study. Journal ofClinical Oncology 30, 958–964.Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H.,Allred, D.C., et al. (2013). Recommendations for human epidermal growth factorreceptor 2 testing in breast cancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. Journal of Clinical Oncology31, 3997–4013.Wolff, A.C., Hammond, M.E., Schwartz, J.N., Hagerty, K.L., Allred, D.C., Cote, R.J.,Dowsett, M., et al. (2007). American Society of Clinical Oncology/College of AmericanPathologists guideline recommendations for human epidermal growth factor receptor2 testing in breast cancer. Archives of Pathology & Laboratory Medicine 131, 18–43.
Pharmacogenomics and Laboratory Medicine141Wrighton, S.A., Brian, W.R., Sari, M.A., Iwasaki, M., Guengerich, F.P., Raucy, J.L.,Molowa, D.T., and Vandenbranden, M. (1990). Studies on the expression and metaboliccapabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology38, 207–213.Xie, H.G., Prasad, H.C., Kim, R.B., and Stein, C.M. (2002). CYP2C9 allelic variants:Ethnic distribution and functional significance. Advanced Drug Delivery Reviews 54,1257–1270.Yaziji, H., Goldstein, L.C., Barry, T.S., Werling, R., Hwang, H., Ellis, G.K., Gralow, J.R.,Livingston, R.B., and Gown, A.M. (2004). HER-2 testing in breast cancer using paralleltissue-based methods. JAMA 291, 1972–1977.Zang, Y., Doll, M.A., Zhao, S., States, J.C., and Hein, D.W. (2007). Functional characterizationof single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2.Carcinogenesis 28, 1665–1671.Zanger, U.M., Raimundo, S., and Eichelbaum, M. (2004). Cytochrome P450 2D6: Overviewand update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Archivesof Pharmacology 369, 23–37.Zanger, U.M., Turpeinen, M., Klein, K., and Schwab, M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analyticaland Bioanalytical Chemistry 392, 1093–1108.Zenser, T.V., Lakshmi, V.M., Rustan, T.D., Doll, M.A., Deitz, A.C., Davis, B.B., andHein, D.W. (1996). Human N-acetylation of benzidine: Role of NAT1 and NAT2.Cancer Research 56, 3941–3947.
Change language